Meet the company that developed the first small molecule drug candidate in Turkey
OncoCube (Delaware, US) was founded by Erden Banoglu, Burcu Çalışkan and Özgür Şahin with the aim of bringing our proprietary anticancer small molecules to the market.
As a significant step forward, TACC3 inhibitors developed in our labs at Gazi and Bilkent Universities were included in the company pipeline. The company has shown proof-of-principle with a small molecule TACC3 inhibitor that has potent anticancer activity in multiple tumor xenograft animal models. OncoCube recently signed a Collaborative Research Agreement with the option to license with a U.S. based drug development company to further develop these TACC3 inhibitors for human clinical studies! Ongoing optimization efforts aim to generate bioavailable TACC3 inhibitors with improved tumor-specificity and pharmacokinetic profiles. OncoCube Therapeutics plans to select their clinicalcandidate for beginning the Investigational New Drug (IND) process in 2021.